Cerevance raises $47m to fund Phase III trial for lead Parkinson’s therapy
US-based Cerevance has secured $47m in Series B-1 extension funding to finance the upcoming Phase III trial for its lead therapy, CVN424. The financiers included multiple US-based venture capital firms such as Google Ventures, Agent Capital, …